At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
DFV890 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
In Brief
A Phase 2 clinical trial evaluating DFV890 and DFV890 Placebo for Coronary Heart Disease. Completed, enrolled 24 participants across 7 sites in 2 countries.
Detailed Summary
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 24 people with known heart disease and an elevated marker of inflammation, hsCRP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Heart Disease
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedSep 2023
Enrollment StartOct 2023
Primary CompletionDec 2024
Study CompletionDec 2024
TodayJul 2026
First PostedSep 11, 2023
Enrollment StartOct 16, 2023
Primary CompletionDec 17, 2024
Study CompletionDec 23, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.8 years ago
Interventions
DFV890drug
Oral film-coated tablets of DFV890 once daily
DFV890 Placebodrug
Oral film-coated tablets of DFV890 placebo once daily